Sign in
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes
Journal article   Open access  Peer reviewed

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

Kevan C Herold, Brian N Bundy, S Alice Long, Jeffrey A Bluestone, Linda A DiMeglio, Matthew J Dufort, Stephen E Gitelman, Peter A Gottlieb, Jeffrey P Krischer, Peter S Linsley, …
The New England journal of medicine, Vol.381(7), pp.603-613
2019-08-15
PMCID: PMC6776880
PMID: 31180194

Abstract

Antibodies, Monoclonal, Humanized - adverse effects Glucose Tolerance Test Antibodies, Monoclonal, Humanized - therapeutic use Diabetes Mellitus, Type 1 - prevention & control Double-Blind Method CD3 Complex - antagonists & inhibitors Humans Middle Aged Proportional Hazards Models Diabetes Mellitus, Type 1 - genetics Male Disease Progression Young Adult HLA-DR3 Antigen Exanthema - chemically induced Adolescent HLA-DR4 Antigen Lymphocyte Count Adult Female T-Lymphocytes - immunology Diabetes Mellitus, Type 1 - immunology Child Lymphopenia - chemically induced
url
https://doi.org/10.1056/NEJMoa1902226View
Published (Version of record) Open

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Highly Cited Paper 
Collaboration types
Domestic collaboration
International collaboration
Citation topics
1 Clinical & Life Sciences
1.26 Diabetes
1.26.1016 Type 1 Diabetes
Web Of Science research areas
Endocrinology & Metabolism
ESI research areas
Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Details